Literature DB >> 24277743

Hepatitis C therapy with interferon-α and ribavirin reduces CD4 T-cell-associated HIV-1 DNA in HIV-1/hepatitis C virus-coinfected patients.

Hong Sun1, Maria J Buzon, Amy Shaw, Randi Karteebahn Berg, Xu G Yu, Sara Ferrando-Martinez, Manuel Leal, Ezequiel Ruiz-Mateos, Mathias Lichterfeld.   

Abstract

Combined treatment with interferon alpha (IFN-α) and ribavirin (RBV) can effectively cure HCV infection in a significant proportion of patients, but effects of this regimen on cellular reservoirs for human immunodeficiency virus type 1 (HIV-1) are unknown. Here, we show that treatment with IFN-α/RBV led to a moderate but significant and sustained decline of HIV-1 DNA in CD4 T cells from HIV-1/hepatitis C virus-coinfected patients receiving highly active antiretroviral therapy (n = 12). However, in vitro experiments failed to demonstrate an effect of pharmacological doses of IFN-α on HIV-1 reactivation. Together, these data suggest that treatment with IFN-α/RBV can moderately reduce the reservoir of HIV-1-infected CD4 T cells that persists despite suppressive antiretroviral therapy.

Entities:  

Keywords:  HIV-1 reservoir; HIV-1/HCV coinfection; interferon-α; ribavirin

Mesh:

Substances:

Year:  2013        PMID: 24277743      PMCID: PMC3982848          DOI: 10.1093/infdis/jit628

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo.

Authors:  Satish K Pillai; Mohamed Abdel-Mohsen; John Guatelli; Mark Skasko; Alexander Monto; Katsuya Fujimoto; Steven Yukl; Warner C Greene; Helen Kovari; Andri Rauch; Jacques Fellay; Manuel Battegay; Bernard Hirschel; Andrea Witteck; Enos Bernasconi; Bruno Ledergerber; Huldrych F Günthard; Joseph K Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

2.  An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.

Authors:  Stuart J D Neil; Virginie Sandrin; Wesley I Sundquist; Paul D Bieniasz
Journal:  Cell Host Microbe       Date:  2007-09-13       Impact factor: 21.023

3.  Alu-LTR real-time nested PCR assay for quantifying integrated HIV-1 DNA.

Authors:  Audrey Brussel; Olivier Delelis; Pierre Sonigo
Journal:  Methods Mol Biol       Date:  2005

4.  Treatment of SIV-infected sooty mangabeys with a type-I IFN agonist results in decreased virus replication without inducing hyperimmune activation.

Authors:  Thomas H Vanderford; Chloe Slichter; Kenneth A Rogers; Benton O Lawson; Rend Obaede; James Else; Francois Villinger; Steven E Bosinger; Guido Silvestri
Journal:  Blood       Date:  2012-05-01       Impact factor: 22.113

5.  Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials.

Authors:  Angela M Mexas; Erin H Graf; Matthew J Pace; Jianqing J Yu; Emmanouil Papasavvas; Livio Azzoni; Michael P Busch; Michele Di Mascio; Andrea S Foulkes; Stephen A Migueles; Luis J Montaner; Una O'Doherty
Journal:  AIDS       Date:  2012-11-28       Impact factor: 4.177

6.  Upregulation of a small subset of genes drives type I interferon-induced antiviral memory.

Authors:  Diego A Jaitin; Gideon Schreiber
Journal:  J Interferon Cytokine Res       Date:  2007-08       Impact factor: 2.607

7.  Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.

Authors:  Livio Azzoni; Andrea S Foulkes; Emmanouil Papasavvas; Angela M Mexas; Kenneth M Lynn; Karam Mounzer; Pablo Tebas; Jeffrey M Jacobson; Ian Frank; Michael P Busch; Steven G Deeks; Mary Carrington; Una O'Doherty; Jay Kostman; Luis J Montaner
Journal:  J Infect Dis       Date:  2012-10-26       Impact factor: 5.226

8.  New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.

Authors:  Sarah Palmer; Ann P Wiegand; Frank Maldarelli; Holly Bazmi; JoAnn M Mican; Michael Polis; Robin L Dewar; Angeline Planta; Shuying Liu; Julia A Metcalf; John W Mellors; John M Coffin
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948

Review 9.  Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR.

Authors:  Megan K Liszewski; Jianqing J Yu; Una O'Doherty
Journal:  Methods       Date:  2009-02-03       Impact factor: 3.608

10.  Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies.

Authors:  Susanne Eriksson; Erin H Graf; Viktor Dahl; Matthew C Strain; Steven A Yukl; Elena S Lysenko; Ronald J Bosch; Jun Lai; Stanley Chioma; Fatemeh Emad; Mohamed Abdel-Mohsen; Rebecca Hoh; Frederick Hecht; Peter Hunt; Ma Somsouk; Joseph Wong; Rowena Johnston; Robert F Siliciano; Douglas D Richman; Una O'Doherty; Sarah Palmer; Steven G Deeks; Janet D Siliciano
Journal:  PLoS Pathog       Date:  2013-02-14       Impact factor: 6.823

View more
  41 in total

Review 1.  Type I interferon: understanding its role in HIV pathogenesis and therapy.

Authors:  Steven E Bosinger; Netanya S Utay
Journal:  Curr HIV/AIDS Rep       Date:  2015-03       Impact factor: 5.071

2.  Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy.

Authors:  Shane D Falcinelli; Bonnie E Shook-Sa; Morgan G Dewey; Sumati Sridhar; Jenna Read; Jennifer Kirchherr; Katherine S James; Brigitte Allard; Simon Ghofrani; Erin Stuelke; Caroline Baker; Nadia R Roan; Joseph J Eron; JoAnn D Kuruc; Catalina Ramirez; Cynthia Gay; Katie R Mollan; David M Margolis; Adaora A Adimora; Nancie M Archin
Journal:  J Infect Dis       Date:  2020-11-09       Impact factor: 5.226

3.  Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.

Authors:  Stéphane Hua; Selena Vigano; Samantha Tse; Ouyang Zhengyu; Sean Harrington; Jordi Negron; Pilar Garcia-Broncano; Giulia Marchetti; Miguel Genebat; Manuel Leal; Salvador Resino; Ezequiel Ruiz-Mateos; Mathias Lichterfeld; Xu G Yu
Journal:  Clin Infect Dis       Date:  2018-06-01       Impact factor: 9.079

4.  Interferon-α alters host glycosylation machinery during treated HIV infection.

Authors:  Leila B Giron; Florent Colomb; Emmanouil Papasavvas; Livio Azzoni; Xiangfan Yin; Matthew Fair; Alitzel Anzurez; Mohammad Damra; Karam Mounzer; Jay R Kostman; Pablo Tebas; Una O'Doherty; Hiroaki Tateno; Qin Liu; Michael R Betts; Luis J Montaner; Mohamed Abdel-Mohsen
Journal:  EBioMedicine       Date:  2020-08-19       Impact factor: 8.143

Review 5.  Control of HIV infection by IFN-α: implications for latency and a cure.

Authors:  Nollaig M Bourke; Silvia Napoletano; Ciaran Bannan; Suaad Ahmed; Colm Bergin; Áine McKnight; Nigel J Stevenson
Journal:  Cell Mol Life Sci       Date:  2017-10-07       Impact factor: 9.261

6.  Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals.

Authors:  Saverio G Parisi; Samantha Andreis; Monica Basso; Silvia Cavinato; Renzo Scaggiante; Marzia Franzetti; Massimo Andreoni; Giorgio Palù; Anna Maria Cattelan
Journal:  Med Microbiol Immunol       Date:  2017-09-01       Impact factor: 3.402

7.  Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.

Authors:  David Palesch; Steven E Bosinger; Maud Mavigner; James M Billingsley; Cameron Mattingly; Diane G Carnathan; Mirko Paiardini; Ann Chahroudi; Thomas H Vanderford; Guido Silvestri
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103

Review 8.  Tetherin/BST-2: Restriction Factor or Immunomodulator?

Authors:  Sam X Li; Bradley S Barrett; Kejun Guo; Mario L Santiago
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

9.  Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

Authors:  M Christian Tjiam; James P A Taylor; Mazmah A Morshidi; Lucy Sariputra; Sally Burrows; Jeffrey N Martin; Steven G Deeks; Dino B A Tan; Silvia Lee; Sonia Fernandez; Martyn A French
Journal:  J Immunol       Date:  2015-04-24       Impact factor: 5.422

10.  Blocking type I interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs.

Authors:  Liang Cheng; Jianping Ma; Jingyun Li; Dan Li; Guangming Li; Feng Li; Qing Zhang; Haisheng Yu; Fumihiko Yasui; Chaobaihui Ye; Li-Chung Tsao; Zhiyuan Hu; Lishan Su; Liguo Zhang
Journal:  J Clin Invest       Date:  2016-12-12       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.